Increased Expression of the Matrix-Modifying Enzyme Lysyl Oxidase-Like 2 in Aggressive Hepatocellular Carcinoma with Poor Prognosis
Gut and Liver
;
: 83-92, 2019.
Article
in English
| WPRIM
| ID: wpr-719363
ABSTRACT
BACKGROUND/AIMS:
Lysyl oxidase-like 2 (LOXL2), a collagen-modifying enzyme, has been implicated in cancer invasiveness and metastasis.METHODS:
We evaluated the expression of LOXL2 protein, in addition to carbonic anhydrase IX (CAIX), keratin 19, epithelial cell adhesion molecule, and interleukin 6, in 105 resected hepatocellular carcinomas (HCCs) by immunohistochemistry.RESULTS:
LOXL2 positivity was found in 14.3% (15/105) of HCCs, and it was significantly associated with high serum α-fetoprotein levels, poor differentiation, fibrous stroma, portal vein invasion, and advanced TNM stage (p < 0.05 for all). Additionally, LOXL2 positivity was significantly associated with CAIX (p=0.005) and stromal interleukin 6 expression (p=0.001). Survival analysis of 99 HCC patients revealed LOXL2 positivity to be a poor prognostic factor; its prognostic impact appeared in progressed HCCs. Furthermore, LOXL2 positivity was shown to be an independent predictor of overall survival and disease-specific survival (p < 0.05 for all). Interestingly, co-expression of LOXL2 and CAIX was also an independent predictor for overall survival, disease-specific survival, disease-free survival, and extrahepatic recurrence-free survival (p < 0.05 for all).CONCLUSIONS:
LOXL2 expression represents a subgroup of HCCs with more aggressive behavior and is suggested to be a poor prognostic marker in HCC patients.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Portal Vein
/
Prognosis
/
Immunohistochemistry
/
Interleukin-6
/
Carbonic Anhydrases
/
Carcinoma, Hepatocellular
/
Disease-Free Survival
/
Epithelial Cells
/
Extracellular Matrix
/
Keratin-19
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Gut and Liver
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS